Efficacy and safety of dovitinib in pediatric patients with osteosarcoma
Latest Information Update: 09 Oct 2023
At a glance
- Drugs Dovitinib (Primary)
- Indications Osteosarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allarity Therapeutics
- 02 Oct 2023 According to an Oncoheroes Biosciences media release, U.S. Food and Drug Administration (FDA) has allowed the Boston-based biotech to begin this clinical trial of dovitinib in pediatric patients with osteosarcoma.
- 02 Oct 2023 According to an Oncoheroes Biosciences media release, company has submitted Investigational New Drug (IND) application to the FDA In August seeking permission to initiate clinical trial.After FDAs thorough review and evaluation, Oncoheroes reported that IND have received the green light from the FDA to move forward.
- 15 Mar 2021 New trial record